TMEM175: lysosomal ion channel physiology, therapeutic potential, and emerging pharmacology
American Journal of Physiology-Cell Physiology · 01.12.2026 · 331 (6) · C1607-C1615
DOI: 10.1152/ajpcell.90012.2026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.12.2026. Verfasst von Kangjun Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States. Hauptthemen laut MEDLINE: Lysosomes, Parkinson Disease, Ion Channels, Antiparkinson Agents. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Department of Anesthesiology at Vanderbilt University Medical Center.
Abstract (Originalsprache)
Transmembrane protein 175 (TMEM175) is a lysosomal cation channel that has emerged as a promising drug target for Parkinson’s disease (PD). Genetic and functional studies linking TMEM175 loss-of-function variants to increased PD risk, lysosomal dysfunction, and α-synuclein accumulation have generated considerable interest in developing pharmacological approaches to enhance channel activity. As a lysosomal cation channel with reported K + and H + permeability, TMEM175 regulates lysosomal membrane potential, pH stability, autophagic flux, and degradative capacity, placing it at a critical control point for cellular proteostasis. Recent advances in high-throughput screening, automated and lysosomal patch clamp electrophysiology, cryoelectron microscopy, and structure-guided medicinal chemistry have transformed TMEM175 from a relatively obscure lysosomal ion channel into a tractable drug target. These approaches have enabled the discovery of multiple classes of TMEM175 modulators while providing new insights into channel gating and mechanisms of activation. In this review, we summarize current progress in TMEM175 pharmacology, including advances in functional assay development and the emerging landscape of tool compounds used to study channel function. We discuss TMEM175 physiology and structure-function relationships, the growing evidence supporting therapeutic intervention, and recent discoveries revealing multiple mechanisms of channel activation. Finally, we highlight key challenges that remain for the field, including the development of potent and selective modulators, opportunities afforded by synergistic channel activation, and the potential application of TMEM175-directed therapeutics beyond Parkinson’s disease in a broader range of neurodegenerative and lysosome-associated disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States.
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
ORCID-Profile: Samantha D Le, Jerod S Denton
Förderung
- Department of Anesthesiology at Vanderbilt University Medical Center
Zitieren
APA
Li, K., Le, S. D., & Denton, J. S. (2026). TMEM175: lysosomal ion channel physiology, therapeutic potential, and emerging pharmacology. American Journal of Physiology-Cell Physiology, 331(6), C1607-C1615. https://doi.org/10.1152/ajpcell.90012.2026
Vancouver
Li K, Le SD, Denton JS. TMEM175: lysosomal ion channel physiology, therapeutic potential, and emerging pharmacology. American Journal of Physiology-Cell Physiology. 2026;331(6):C1607-C1615. doi:10.1152/ajpcell.90012.2026
BibTeX
@article{Li2026,
author = {Li, Kangjun and Le, Samantha D and Denton, Jerod S},
title = {TMEM175: lysosomal ion channel physiology, therapeutic potential, and emerging pharmacology},
journal = {American Journal of Physiology-Cell Physiology},
year = {2026},
volume = {331},
number = {6},
pages = {C1607--C1615},
doi = {10.1152/ajpcell.90012.2026}
}
EUVIMED